/
NRIX
$23.85+$0.95 (+4.15%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$2.4B
103M shares
52-week range
$8.20 – $24.03
99% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.30%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-2.68
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $37.4M | $31.1M | $17.8M | $29.8M | $38.6M | $77.0M | $54.5M | $84.0M |
| Cost of revenue | $40.5M | $45.0M | $66.5M | $116.4M | $184.5M | $189.1M | $221.6M | $18.9M |
| Gross profit | −$3.1M | −$13.9M | −$48.7M | −$86.7M | −$145.9M | −$112.2M | −$167.1M | $65.1M |
| Gross margin | -8.2% | -44.7% | -273.1% | -291.4% | -377.6% | -145.7% | -306.3% | 77.5% |
| R&D | $40.5M | $45.0M | $66.5M | $116.4M | $184.5M | $189.1M | $221.6M | $308.2M |
| Operating income | −$9.7M | −$22.2M | −$65.0M | −$117.9M | −$183.9M | −$155.1M | −$213.0M | −$285.7M |
| EBITDA | −$6.8M | −$19.9M | −$62.8M | −$115.1M | −$176.2M | −$137.8M | −$185.3M | −$244.8M |
| Net income | −$9.4M | −$21.7M | −$43.2M | −$117.2M | −$180.4M | −$143.9M | −$193.6M | −$264.5M |
| Net margin | -25.2% | -69.7% | -242.7% | -393.9% | -466.9% | -187.0% | -354.9% | -314.9% |
| EPS (diluted) | -0.59 | -0.56 | -2.76 | -2.73 | -3.71 | -2.65 | -2.88 | -3.05 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $106M | $-2.50 | $-2.77–$-2.25 | 12 |
| 2027 | $82M | $-2.39 | $-3.13–$-1.80 | 11 |
| 2028 | $180M | $-1.53 | $-3.48–$3.22 | 10 |
| 2029 | $252M | $-1.46 | $-6.21–$-0.19 | 4 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Nurix Therapeutics, Inc. Common stock
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
www.nurixtx.com- Employees
- 357
- IPO / List date
- Jul 24, 2020
- HQ
- BRISBANE, CA
Held by traders on TradeandTell
No one on the platform currently holds NRIX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 118,000 | $1.8M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded NRIX yet.
